Supernus Announces Issuance of Third US Patent Protecting Trokendi XR™
ROCKVILLE, Md. -- March 12, 2014
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical
company focused on developing and commercializing products for the treatment
of central nervous system diseases, today announced the issuance of a third
patent (number 8,663,683) by the United States Patent and Trademark Office
(USPTO) covering Trokendi XR™, its novel once-daily extended-release
topiramate product. The patent was issued by the USPTO on March 04, 2014. It
provides protection for the product with expiration that is no earlier than
“We continue to place great importance on expanding and protecting our
intellectual property to ensure the sustainability and longevity of our
products. The issuance of this patent provides us with a broadened proprietary
position with respect to our extended release formulation of topiramate. We
now have patent protection on Oxtellar XR^® and Trokendi XR™ through three
issued U.S. patents each, and are focused on further expanding such
protection,” saidJack A. Khattar, President and CEO of Supernus.
Supernus has several additional patent applications for extended-release
topiramate and extended-release oxcarbazepine pending in other geographic
Trokendi XR is the only approved novel once-daily extended release formulation
of topiramate for the treatment of epilepsy. Trokendi XR is an antiepileptic
drug indicated for initial monotherapy in patients 10 years of age and older
with partial onset or primary generalized tonic-clonic seizures; adjunctive
therapy in patients 6 years of age and older with partial onset or primary
generalized tonic-clonic seizures; and adjunctive therapy in patients 6 years
of age and older with seizures associated with Lennox-Gastaut syndrome. The
product is available in 25mg, 50mg, 100mg and 200mg extended-release capsules.
For full prescribing and safety information,click here.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on developing and commercializing products for the treatment of central
nervous system, or CNS, diseases. The Company has two marketed products for
epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR™
(extended-release topiramate). The Company is also developing several product
candidates in psychiatry to address large market opportunities in ADHD,
including ADHD patients with impulsive aggression. These product candidates
include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.
Forward Looking Statements
This press release contains forward-looking statements regarding the potential
of Trokendi XR and Oxtellar XR and intellectual property protection. Actual
results may differ materially from those in these forward-looking statements
as a result of various factors, including, but not limited to, risks regarding
the company's ability to commercialize the product successfully, whether
physicians will prescribe and patients will use the product, and competition
in the market. For a further description of these and other risks facing the
Company, please see the risk factors described in the Company's Annual Report
Form 10-K that was filed with the United States Securities and Exchange
Commission on March 15, 2013 and under the caption "Risk Factors" and the
updates to these risk factors in the Company's quarterly report form 10-Q that
was filed with the Commission on August 14, 2013. Forward-looking statements
speak only as of the date of this press release, and the company undertakes no
obligation to update or revise these statements, except as may be required by
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
Press spacebar to pause and continue. Press esc to stop.